Recently, Hansoh Pharma was included in the first “Sustainability Yearbook (China)” published by S&P Global, ranking in the Top 1% for its S&P Global ESG score and gained recognition as an “Industry Mover”.
According to the assessments of the Sustainability Yearbook, these two achievements mean that Hansoh Pharma outperformed other Chinese pharmaceutical companies in terms of CSA score (63) in 2022, and made the biggest improvement in the sector. Hansoh Pharma was included in the S&P Sustainability Yearbook (Global) previously, and was the only pharmaceutical company in Chinese Mainland to be selected.
Initiated by S&P Global, the Corporate Sustainability Assessment (CSA) is one of the world's leading annual evaluations of companies' sustainability practices, and is rapidly extending its influence both in China and internationally as global stakeholders continue to focus on ESG. A record number of companies participated in the CSA in 2022, with the number of participating companies in China’s Mainland, Hong Kong SAR, and Macau SAR exceeding 1,600, roughly triple the number of participants in 2021. Among these companies, Hansoh Pharma stands out for its excellent sustainability practices and has been highly recognized by international authorities, further strengthening the company's confidence and determination to continue its efforts in the field of ESG.
Hansoh Pharma, a top-ranked innovation-driven pharmaceutical company headquartered in China, is committed to improving its policies and systems and enhancing its ESG management system, including governance structure and strategy, product safety and quality, human resources and development, climate action and low-carbon environmental protection, and corporate social responsibility, so as to build long-term momentum to drive the company's global innovation.
The company has always been committed to becoming a pioneer in global pharmaceutical innovation, a deep cultivator of the health industry, and an advocate of green power. While constantly improving the quality of human life, the company strives to create diversified social values and comprehensively improve economic, social, and ecological benefits.
